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We present a case of living donor liver transplantation to a 3-year disease-free survivor of liver resec-
tion for hepatocellular carcinoma (HCC) with major portal vein invasion.  A 48-year-old man had HCC 
in the right lobe with a portal venous tumor thrombus extending into the left portal vein.  An extended 
right lobectomy with thrombectomy was performed to remove the thrombus.  Three years after liver 
resection,  the patient experienced liver failure,  with massive ascites and jaundice due to the formation 
of a thrombus in the main and left portal veins.  During the 3 years after liver resection,  no metastasis 
or recurrence of HCC had been detected,  and tumor markers had been within normal ranges.  The 
portal venous thrombus did not show any arterial enhancement under contrast-enhanced computed 
tomography,  suggesting that the co-existence of any HCC component in the portal venous thrombus 
may have been negative.  Based on these ﬁndings,  living donor liver transplantation was performed 
using a right lobe graft from the patientʼs son.  The patient is alive at 87 months after the transplanta-
tion,  with no evidence of HCC recurrence.
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he outcome of liver transplantation for patients 
having previously undergone liver resection for 
hepatocellular carcinoma (HCC) has been investigated 
[1-3].  In many of those patients,  the HCC was 
reported to be within the Milan criteria (a solitary 
liver nodule not exceeding 5cm in maximum diameter,  
or 2 or 3 tumors not exceeding 3cm in diameter) both 
at the time of liver resection and at the time of liver 
transplantation.  Patients who have HCC with macro-
scopic vascular invasion are contraindicated for liver 
transplantation because the rate of HCC recurrence 
after liver transplantation in such cases is extremely 
high [4-8].
　 Portal venous tumor thrombus (PVTT) is one of 
the most ominous prognostic factors in patients with 
HCC [9-14].  Even when curative liver resection with 
thrombectomy for PVTT can be carried out,  long-
term patient survival after such liver resections has 
still been poor.  However,  10ｵ to 20ｵ of patients 
who received liver resection for HCC with PVTT 
have shown long-term survival with no tumor recur-
rence [11-14].
　 We report a case of living donor liver transplanta-
tion (LDLT) to a 3-year disease-free survivor of liver 
T
Acta Med.  Okayama,  2013
Vol.  67,  No.  2,  pp.  117ﾝ121
CopyrightⒸ 2013 by Okayama University Medical School.
Case Report http ://escholarship.lib.okayama-u.ac.jp/amo/
Received September 11, 2012 ; accepted October 31, 2012.
＊Corresponding author. Phone : ＋81ﾝ86ﾝ235ﾝ7257; Fax : ＋81ﾝ86ﾝ221ﾝ8775
E-mail : sada@md.okayama-u.ac.jp (H. Sadamori)
resection for HCC with PVTT extending into the 
contralateral portal vein.  At 87 months after LDLT,  
this patient is currently alive and well,  with no evi-
dence of HCC recurrence.
Case Report
　 A 48-year-old man was diagnosed with hepatitis B 
virus infection.  In January 2002,  computed tomogra-
phy (CT) scans revealed HCC with a diameter of 
7.0cm located in the anterior and medial segments,  
whereupon the HCC was treated with transarterial 
chemoembolization using lipiodol and epirubicin (Fig.  
1A).  Additionally,  the PVTT derived from the main 
HCC ﬁlled the right portal vein and extended into the 
left portal vein (Fig.  1B).  No intra-hepatic metastasis 
of HCC was detected.  The serology of the hepatitis B 
virus (HBV) was as follows: hepatitis B surface anti-
gen (＋),  hepatitis B surface antibody (－),  hepatitis 
Be antigen (－),  hepatitis Be antibody (＋),  and hepa-
titis B core antibody (＋).  The level of HBV DNA in 
the blood was less than 3.7LGE/mL as measured by 
the transcription-mediated ampliﬁcation method.  The 
serum level of alpha-fetoprotein (AFP) was elevated 
at 853ng/mL.  The serum level of protein induced by 
vitamin K absence or antagonist (PIVKA-II) was 
54mAU/mL (normal laboratory range is ＜28mAU/
mL).  In March 2002,  because the liver function of this 
patient was well preserved and the remnant liver vol-
ume was suﬃcient,  an extended right lobectomy with 
thrombectomy for PVTT was performed.  Macroscopic 
and histological examinations of the resected specimen 
showed a moderately diﬀerentiated HCC with PVTT 
extending into the left portal vein (Fig.  1C).  The 
postoperative clinical course was uneventful,  and 
postoperative checkups including ultrasonography 
and/or CT scans were performed every 3 months 
after discharge.
　 In November 2004,  the level of HBV DNA was 
elevated to 2.9 log copy/mL as measured by the poly-
merase chain reaction method,  and the serum total 
bilirubin level increased to around 3.0mg/dL.  Anti-
viral treatment with lamivudine (100mg daily) was 
commenced.  In February 2005,  the patient developed 
massive ascites,  and the serum total bilirubin level 
increased to 5.7mg/dL.  CT scans showed a mural 
thrombus,  occupying one-fourth of the main portal vein 
and extending to the left portal vein (Fig.  2A).  Also,  
a localized thrombus was detected in the umbilical 
portion of the portal vein,  occluding most of the 
lumen (Fig.  2B).  The portal venous thrombus did not 
show any arterial enhancement on contrast-enhanced 
CT scans.  Additionally,  the serum AFP and 
PIVKA-II concentrations were within the normal 
ranges.  These ﬁndings suggested that the co-existence 
of an HCC component in the portal venous thrombus 
may have been negative.  Anti-coagulation therapy with 
warfarin was commenced for the portal venous throm-
bus.
　 Although the thrombus was reduced by about half 
at 1 month after the initiation of anti-coagulation 
therapy,  the massive ascites did not diminish and the 
serum total bilirubin level increased to 6.0mg/dL.  In 
April 2005,  the patientʼs model for end-stage liver 
disease score was 18 and his Child-Pugh score was 11.  
No metastasis or recurrence of HCC in the remnant 
liver or to other organs was detected through magnetic 
resonance imaging,  CT scans,  bone scintigraphy,  and 
positron emission tomography CT.  Because liver 
failure had developed in spite of medical treatment and 
there had been no evidence of HCC recurrence during 
the 3 years after liver resection,  the decision was 
made to perform LDLT.
　 In May 2005,  LDLT was performed using a right 
lobe graft from the patientʼs son.  The graft weighed 
690g,  and the graft weight/recipient weight ratio was 
1.1ｵ.  There were severe adhesions around the rem-
nant liver and the hepatoduodenal ligament.  In addi-
tion,  the wall of the main portal vein was extremely 
thin and fragile due to the previous liver resection.  
Therefore,  the recipientʼs main portal vein was 
removed and portal venous reconstruction was per-
formed by interposing the left internal jugular vein 
graft (Fig.  3).  The operative time was 645 min,  and 
the intraoperative blood loss was 3,800mL.  
Histological examination of the removed specimen 
showed liver cirrhosis.  There was no evidence of 
HCC recurrence in the removed liver or in the throm-
bus of the main and left portal veins.  Although acute 
cellular rejection requiring steroid pulse therapy 
developed on postoperative day 9,  the patient was 
discharged on postoperative day 21.  He is currently 
alive and well with no evidence of HCC recurrence at 
87 months after LDLT.
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Discussion
　 Liver transplantation has been performed for 
patients who had previously undergone liver resection 
for HCC.  In many of those patients,  the HCC was 
within the Milan criteria both at the time of liver 
resection and at the time of liver transplantation 
because of the low rates of tumor recurrence after 
liver transplantation [1-3].  On the other hand,  liver 
transplantation is contraindicated in patients having 
HCC with major vascular invasion because of the high 
rates of tumor recurrence and the associated poor 
long-term survival [4-8].  Therefore,  for those 
patients,  liver resection remains the only therapeutic 
option that may oﬀer a chance for disease-free sur-
vival.  In this study,  we report a case of LDLT to a 
3-year disease-free survivor of liver resection for 
HCC with PVTT extending into the contralateral 
portal vein.  At 87 months after LDLT,  this patient 
is currently alive,  with no evidence of HCC recur-
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Fig. 1　 Computed tomography (CT) images before liver resection,  
and macroscopic examination of the resected specimen.  A,  
Dynamic CT scan showed hepatocellular carcinoma (HCC) with a 
diameter of 7.0cm located in the anterior and medial segments; the 
HCC was then treated with transarterial chemoembolization using 
lipiodol and epirubicin; B,  Portal venous tumor thrombus (arrow) 
derived from the main HCC extended into the left portal vein; C,  
Macroscopic examination of the resected liver specimen revealed 
portal venous tumor thrombus (arrowhead) ﬁlling the right portal 
vein.
Left internal
jugular vein graft
Main portal vein
of the recipient
Fig. 3　 Interposition using the left internal jugular vein graft was 
performed for portal venous reconstruction of the liver graft.
rence.  Thus it is a rare case of long-term disease-free 
survival through liver resection and LDLT.  
　 The indication for liver transplantation in patients 
who have disease-free survival after liver resection for 
HCC with major vascular invasion is controversial and 
diﬃcult.  This is because the rate of HCC recurrence 
after liver transplantation cannot be estimated in those 
patients.  Although the prognosis after liver resection 
for HCC with major vascular invasion remains poor,  
some patients (10ｵ-20ｵ) are reported to have long-
term survival without tumor recurrence [11-14].  
According to these studies,  in most cases,  tumor 
recurrence develops within 2 years of liver resection,  
and the disease-free survival rate tends to be 
unchanged 3 years and onwards following liver resec-
tion.  In the present case,  as a result of systemic 
imaging,  there was no evidence of HCC recurrence 
during the 3 years after liver resection for HCC with 
PVTT.  Additionally,  the ﬁndings of contrast-
enhanced CT scans,  which showed no arterial 
enhancement in the portal venous thrombus,  suggested 
that the co-existence of any HCC component in the 
portal venous thrombus may have been negative.  
Although the eﬀect of immunosuppression on tumor 
recurrence after liver transplantation could not be 
estimated in the present case,  we believe that the risk 
of HCC recurrence after LDLT was low.
　 Previous studies have reported that,  in most cases,  
liver transplantation is performed as a rescue therapy 
for intra-hepatic recurrences after liver resection for 
HCC [1, 15, 16].  On the other hand,  in the present 
case LDLT was performed for chronic liver failure 
without HCC recurrence,  resulting in a relatively 
rare indication for liver transplantation after liver 
resection for HCC.  Mergental et al.  [15] suggested 
that macrovascular invasion,  lymph node involvement,  
and time interval between liver resection and trans-
plantation ＜12 months were independently associated 
with poor overall and tumor-free survival rates after 
liver transplantation.  Those authors suggested that the 
presence of any of these 2 risk factors should be con-
sidered a contraindication for liver transplantation 
after liver resection for advanced HCC [15].  
Although the present case had HCC with macrovascu-
lar invasion at liver resection,  LDLT was performed 
for chronic liver failure because there had been no 
evidence of HCC recurrence during the 3 years after 
liver resection.
　 Belghiti et al.  [1] analyzed the inﬂ uence of previ-
ous liver resection for HCC on the outcome of liver 
transplantation.  They reported that liver transplanta-
tion following major liver resection appeared to be 
more diﬃcult,  resulting in longer operating time,  
increased blood transfusion rate,  and longer hospital 
stay.  In the present case,  interposition using the 
internal jugular vein graft was necessary for portal 
venous reconstruction because the wall of the main 
portal vein became fragile due to the previous liver 
resection.
　 In this patient,  the combination of liver resection 
and LDLT were eﬀective for obtaining disease-free 
long-term survival.  Further investigations,  including 
molecular and genomic analyses,  will be necessary to 
reﬁne the indication for liver transplantation in dis-
ease-free survivors of liver resection for advanced 
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Fig. 2　 Computed tomography (CT) images before living donor 
liver transplantation.  A,  The thrombus was found on the left wall of 
the main and left portal veins (arrow), with massive ascites and 
severe splenomegaly; B,  The localized thrombus (arrowhead) was 
detected in the umbilical portion of the portal vein,  occluding most 
of the lumen.
HCC with major vascular invasion.
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